On 6/29/2016, Galena Biopharma, Inc. (NASDAQ:GALE) ended trading session lower at $0.35 with -82.76%. The company traded a volume of 79.88 million shares as comparison to average volume of 3.1 million shares.
Glaxo has had a tough time of late as blockbuster drugs finish patents, which has caused cash flow to decrease. The company has moved to offset this and now has an exciting pipeline of new drugs and treatments set to hit the market in the next few years.
GlaxoSmithKline(LSE: GSK) is one such company. The pharmaceuticals giant is a world leader in the production of consumer pharmaceutical products, such as over-the-counter medicines, toothpaste and painkillers.
Credit Suisse gave the share price of GlaxoSmithKline PLC a price target of 1440 meaning the broker expects a potential downside of -2.83% from GlaxoSmithKline PLC's current market price of 1482. GlaxoSmithKline PLC has 4,858,000,000 shares ...
There's been much talk in recent years of GlaxoSmithKline's drugs pipeline. There have been several medicine launches in recent years, yet none has turned into a blockbuster to match the success of treatments like Zantac.